161 related articles for article (PubMed ID: 24565737)
21. Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
Cover J; Ba M; Drake JK; NDiaye MD
Contraception; 2019 Feb; 99(2):137-141. PubMed ID: 30439358
[TBL] [Abstract][Full Text] [Related]
22. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector.
Liu J; Schatzkin E; Omoluabi E; Fajemisin M; Onuoha C; Erinfolami T; Ayodeji K; Ogunmola S; Shen J; Diamond-Smith N; Sieverding M
Contraception; 2018 Nov; 98(5):438-448. PubMed ID: 30071196
[TBL] [Abstract][Full Text] [Related]
23. Acceptability of the community-level provision of Sayana® Press by medical and nursing students in Kinshasa, Democratic Republic of the Congo.
Bertrand JT; Makani PB; Hernandez J; Akilimali P; Mukengeshayi B; Babazadeh S; Binanga A
Contraception; 2017 Sep; 96(3):211-215. PubMed ID: 28647500
[TBL] [Abstract][Full Text] [Related]
24. Pilot Research as Advocacy: The Case of Sayana Press in Kinshasa, Democratic Republic of the Congo.
Binanga A; Bertrand JT
Glob Health Sci Pract; 2016 Dec; 4(4):542-551. PubMed ID: 27979874
[TBL] [Abstract][Full Text] [Related]
25. Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.
Cover J; Namagembe A; Tumusiime J; Lim J; Cox CM
Reprod Health; 2018 Oct; 15(1):165. PubMed ID: 30285779
[TBL] [Abstract][Full Text] [Related]
26. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
27. Injectable contraception: emerging evidence on subcutaneous self-administration.
Lerma K; Goldthwaite LM
Curr Opin Obstet Gynecol; 2019 Dec; 31(6):464-470. PubMed ID: 31567445
[TBL] [Abstract][Full Text] [Related]
28. [Community-based distribution of injectable contraceptives in an African setting: community trial in Madagascar].
Brunie A; Hoke TH; Razafindravony B
Sante; 2011; 21(1):21-6. PubMed ID: 21550921
[TBL] [Abstract][Full Text] [Related]
29. Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem.
Bahamondes L; Marchi NM; Nakagava HM; de Melo ML; Cristofoletti Mde L; Pellini E; Scozzafave RH; Petta C
Contraception; 1997 Nov; 56(5):301-4. PubMed ID: 9437558
[TBL] [Abstract][Full Text] [Related]
30. The feasibility of contraceptive injections at the community pharmacy.
Heller R; Johnstone A; Cameron ST
Eur J Contracept Reprod Health Care; 2017 Oct; 22(5):327-333. PubMed ID: 28849961
[TBL] [Abstract][Full Text] [Related]
31. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
Cameron ST; Glasier A; Johnstone A
Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
[TBL] [Abstract][Full Text] [Related]
33. Acceptability of the distribution of DMPA-SC by community health workers among acceptors in the rural province of Lualaba in the Democratic Republic of the Congo: a pilot study.
Mwembo A; Emel R; Koba T; Sankoko JB; Ngay A; Gay R; Bertrand JT
Contraception; 2018 Nov; 98(5):454-459. PubMed ID: 30118683
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
35. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
36. Provision of DMPA by community health workers: what the evidence shows.
Malarcher S; Meirik O; Lebetkin E; Shah I; Spieler J; Stanback J
Contraception; 2011 Jun; 83(6):495-503. PubMed ID: 21570545
[TBL] [Abstract][Full Text] [Related]
37. Scaling up community provision of injectables through the public sector in Uganda.
Krueger K; Akol A; Wamala P; Brunie A
Stud Fam Plann; 2011 Jun; 42(2):117-24. PubMed ID: 21834413
[TBL] [Abstract][Full Text] [Related]
38. Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda.
Cover J; Lim J; Namagembe A; Tumusiime J; Drake JK; Cox CM
Int Perspect Sex Reprod Health; 2017 Dec; 43(4):153-162. PubMed ID: 29771679
[TBL] [Abstract][Full Text] [Related]
39. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
Katz M; Newmark RL; Aronstam A; O'Grady N; Strome S; Rafie S; Karlin J
Contraception; 2020 Dec; 102(6):392-395. PubMed ID: 32931811
[TBL] [Abstract][Full Text] [Related]
40. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
